0000899243-19-029824.txt : 20191220
0000899243-19-029824.hdr.sgml : 20191220
20191220185306
ACCESSION NUMBER: 0000899243-19-029824
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191112
FILED AS OF DATE: 20191220
DATE AS OF CHANGE: 20191220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DRACHMAN JONATHAN G
CENTRAL INDEX KEY: 0001588467
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 191303137
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-732-2133
MAIL ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
DATE OF NAME CHANGE: 20140128
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-12
0
0001404644
Neoleukin Therapeutics, Inc.
NLTX
0001588467
DRACHMAN JONATHAN G
C/O NEOLEUKIN THERAPEUTICS, INC.
1616 EASTLAKE AVENUE E., #360
SEATTLE
WA
98102
1
1
0
0
President and CEO
Series A Preferred Stock
2019-11-12
4
C
0
12616
0.00
D
0
D
Common Stock
2019-11-12
4
C
0
1261600
0.00
A
2079639
D
Common Stock
2019-12-20
4
P
0
119047
8.40
A
2198686
D
Each share of Series A Convertible Preferred Stock converted into 100 shares of the Issuer's Common Stock upon the approval of the Issuer's stockholders on November 12, 2019.
Represents shares purchased in an underwritten public offering of the Issuer's Common Stock.
/s/ Kamran Alam, Attorney-in-fact for Jonathan G. Drachman
2019-12-20